{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Dermira%2C+Inc.",
    "query": {
      "sponsor": "Dermira, Inc."
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Dermira%2C+Inc.&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-03T23:32:19.416Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03073486",
      "title": "A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Olumacostat Glasaretil Gel, 5.0%",
          "type": "DRUG"
        },
        {
          "name": "Olumacostat Glasaretil Gel, Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dermira, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "9 Years and older"
      },
      "enrollment_count": 744,
      "start_date": "2017-02-06",
      "completion_date": "2017-12-21",
      "has_results": true,
      "last_update_posted_date": "2021-07-20",
      "last_synced_at": "2026-10-03T23:32:19.416Z",
      "location_count": 36,
      "location_summary": "Guntersville, Alabama • Glendale, Arizona • Bryant, Arkansas + 32 more",
      "locations": [
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Bryant",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Fremont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03073486"
    },
    {
      "nct_id": "NCT03028363",
      "title": "A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Olumacostat Glasaretil Gel, 5.0%",
          "type": "DRUG"
        },
        {
          "name": "Olumacostat Glasaretil Gel, Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dermira, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "9 Years and older"
      },
      "enrollment_count": 759,
      "start_date": "2016-12-27",
      "completion_date": "2017-11-28",
      "has_results": true,
      "last_update_posted_date": "2021-07-20",
      "last_synced_at": "2026-10-03T23:32:19.416Z",
      "location_count": 38,
      "location_summary": "Phoenix, Arizona • Anaheim, California • Los Angeles, California + 30 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03028363"
    },
    {
      "nct_id": "NCT02431052",
      "title": "A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Olumacostat Glasaretil",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dermira, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 420,
      "start_date": "2015-04",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2021-07-20",
      "last_synced_at": "2026-10-03T23:32:19.416Z",
      "location_count": 28,
      "location_summary": "Mobile, Alabama • Encino, California • San Diego, California + 24 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "North Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Sanford",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02431052"
    },
    {
      "nct_id": "NCT03443024",
      "title": "A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Lebrikizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 280,
      "start_date": "2018-01-30",
      "completion_date": "2019-05-23",
      "has_results": true,
      "last_update_posted_date": "2021-05-04",
      "last_synced_at": "2026-10-03T23:32:19.416Z",
      "location_count": 58,
      "location_summary": "Scottsdale, Arizona • Bryant, Arkansas • Rogers, Arkansas + 51 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bryant",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03443024"
    },
    {
      "nct_id": "NCT04392154",
      "title": "Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Lebrikizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1153,
      "start_date": "2020-06-15",
      "completion_date": "2025-04-22",
      "has_results": true,
      "last_update_posted_date": "2025-11-05",
      "last_synced_at": "2026-10-03T23:32:19.416Z",
      "location_count": 160,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 124 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04392154"
    },
    {
      "nct_id": "NCT04250350",
      "title": "Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Lebrikizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 206,
      "start_date": "2020-02-11",
      "completion_date": "2022-06-22",
      "has_results": true,
      "last_update_posted_date": "2023-02-24",
      "last_synced_at": "2026-10-03T23:32:19.416Z",
      "location_count": 48,
      "location_summary": "Anniston, Alabama • North Little Rock, Arkansas • Canoga Park, California + 38 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04250350"
    },
    {
      "nct_id": "NCT04250337",
      "title": "Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Lebrikizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Topical Corticosteroid",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 228,
      "start_date": "2020-02-03",
      "completion_date": "2021-09-16",
      "has_results": true,
      "last_update_posted_date": "2022-05-09",
      "last_synced_at": "2026-10-03T23:32:19.416Z",
      "location_count": 43,
      "location_summary": "Scottsdale, Arizona • Anaheim, California • Bakersfield, California + 32 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04250337"
    },
    {
      "nct_id": "NCT03127956",
      "title": "A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Olumacostat Glasaretil Gel, 5.0%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dermira, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "9 Years and older"
      },
      "enrollment_count": 748,
      "start_date": "2017-03-21",
      "completion_date": "2018-04-27",
      "has_results": true,
      "last_update_posted_date": "2021-07-20",
      "last_synced_at": "2026-10-03T23:32:19.416Z",
      "location_count": 73,
      "location_summary": "Guntersville, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more",
      "locations": [
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bryant",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03127956"
    },
    {
      "nct_id": "NCT04178967",
      "title": "Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Lebrikizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 445,
      "start_date": "2019-10-29",
      "completion_date": "2022-04-28",
      "has_results": true,
      "last_update_posted_date": "2023-05-24",
      "last_synced_at": "2026-10-03T23:32:19.416Z",
      "location_count": 40,
      "location_summary": "Scottsdale, Arizona • Rogers, Arkansas • Bakersfield, California + 35 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04178967"
    },
    {
      "nct_id": "NCT01830764",
      "title": "Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Red Light (PDT)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dermira, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2013-04",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2021-07-20",
      "last_synced_at": "2026-10-03T23:32:19.416Z",
      "location_count": 1,
      "location_summary": "Paramus, New Jersey",
      "locations": [
        {
          "city": "Paramus",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01830764"
    }
  ]
}